By SPC Staff
The monoclonal antibody tezepelumab-ekko (Tezspire, Amgen and AstraZeneca) received a new indication to allow self-administration in a prefilled, single-use pen for patients ages 12 years and older with severe asthma.
The antibody was previously approved in December 2021, to be administered by a healthcare provider every four weeks. Tezepelumab-ekko is the first severe asthma treatment with no phenotype or biomarker limitation.